# A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

> **NCT04032704** · PHASE2 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 205 (actual)

## Conditions studied

- Small Cell Lung Cancer
- Non-small Cell Lung Cancer, Squamous
- Non-small Cell Lung Cancer, Non-squamous
- Head and Neck Squamous Cell Carcinoma
- Esophageal Squamous Cell Carcinoma
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Prostate Cancer
- Melanoma

## Interventions

- **DRUG:** ladiratuzumab vedotin
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT04032704
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-09
- **Primary completion:** 2023-11-28
- **Final completion:** 2023-11-28
- **Target enrollment:** 205 (ACTUAL)
- **Why stopped:** Study closed due to portfolio prioritization
- **Last updated:** 2025-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04032704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04032704, "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04032704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*